LTRN Lantern Pharma

Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. It leverages advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I. platform to discover biomarker signatures that help identify patients more likely to respond to its pipeline of cancer therapeutics. Lantern's focus is to improve the outcome for patients by leveraging its technology to uncover, rescue and develop abandoned or failed drugs. Its current pipeline of three drugs, with two programs in clinical stages and two in preclinical, focuses on cancers that have unique and unmet clinical needs with a clearly defined patient population. It believes that the use of machine learning, genomics and computational methods can help accelerate the revitalization, refocusing and development of small molecule-based therapies. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, this approach represents the potential to deliver best-in-class outcomes. Its team seeks out experienced industry partners, world-class scientific advisors, and innovative clinical-regulatory approaches to assist in delivering cancer therapies to patients as quickly and efficiently as possible.

Company profile

Panna L. Sharma
Fiscal year end
Former names
Lantern Pharma
Lantern Pharma Limited ...
IRS number

LTRN stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


29 Jul 21
20 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 61.35M 61.35M 61.35M 61.35M 61.35M 61.35M
Cash burn (monthly) 6.67M (positive/no burn) 826.36K 794.07K 772.16K 347.53K
Cash used (since last report) 24.72M n/a 3.06M 2.94M 2.86M 1.29M
Cash remaining 36.63M n/a 58.29M 58.41M 58.49M 60.07M
Runway (months of cash) 5.5 n/a 70.5 73.6 75.8 172.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Jun 20 Keyser D Jeffrey Common Stock Conversion Acquire C No No 0 31,927 0 41,927
15 Jun 20 Keyser D Jeffrey Stock Option Common Stock Grant Acquire A No No 15 9,135 137.03K 9,135
15 Jun 20 Keyser D Jeffrey Series A Preferred Stock Common Stock Conversion Dispose C No No 0 18,349 0 0
15 Jun 20 David R. Margrave Stock Option Common Stock Grant Acquire A No No 15 78,300 1.17M 78,300
15 Jun 20 Prendergast Franklyn G Stock Option Common Stock Grant Acquire A No No 15 9,135 137.03K 9,135

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

23.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 24 27 -11.1%
Opened positions 3 19 -84.2%
Closed positions 6 2 +200.0%
Increased positions 13 4 +225.0%
Reduced positions 2 2
13F shares
Current Prev Q Change
Total value 39.93M 45.73M -12.7%
Total shares 2.57M 2.63M -2.2%
Total puts 0 0
Total calls 0 17.9K EXIT
Total put/call ratio
Largest owners
Shares Value Change
Empery Asset Management 700K $10.16M 0.0%
Corriente Advisors 656.36K $9.58M -8.0%
Green Park & Golf Ventures 525.26K $10.11M 0.0%
Vanguard 269.43K $3.93M +4.0%
GWM Advisors 151.32K $2.21M NEW
Geode Capital Management 55.48K $809K +21.1%
MS Morgan Stanley 52.3K $764K +3.2%
Redmond Asset Management 45.5K $664K +1.1%
Wolff Wiese Magana 28.32K $413K +4.6%
BK Bank Of New York Mellon 26.77K $391K +127.3%
Largest transactions
Shares Bought/sold Change
GWM Advisors 151.32K +151.32K NEW
Flagship Harbor Advisors 0 -147.67K EXIT
Corriente Advisors 656.36K -57.44K -8.0%
Millennium Management 0 -42.11K EXIT
BK Bank Of New York Mellon 26.77K +14.99K +127.3%
Citadel Advisors 0 -11.19K EXIT
Vanguard 269.43K +10.28K +4.0%
Geode Capital Management 55.48K +9.65K +21.1%
UBS UBS Group AG - Registered Shares 8.24K +6.08K +280.6%
WFC Wells Fargo & Co. 7.42K +3.78K +103.8%

Financial report summary

Evaxion Biotech A/S
Content analysis
H.S. sophomore Avg
New words: agency, assessed, assessment, automatically, bladder, bore, borrowing, broker, caption, carrying, classification, companion, comprehensive, contractual, corroboration, decline, diagnostic, discretion, dividend, eligible, escrow, evidence, expedient, guide, hierarchy, identical, identification, impairment, implicit, indirectly, individual, input, IP, landlord, length, lowest, minimum, mutation, mutual, NAV, nominal, orderly, practical, protocol, quoted, reacquire, readily, realized, recipient, reconciliation, reevaluate, ROU, sell, separate, suffer, terminate, twelve, unadjusted, underlying, unrealized, varying, written
Removed: accelerated, allocation, anniversary, arise, attestation, auditor, aware, complying, continuing, deemed, diversion, earliest, emerging, enacted, filer, firm, involved, iv, Jumpstart, large, mandatory, nonconvertible, ordinary, PCAOB, pending, priority, proceeding, reduced, requirement, revised, rotation, set, supplement, system, tax, threatened, transition, unpaid